121 Bio, LLC
121 Bio, LLC, is a Cambridge-based biopharmaceutical start-up company that is developing a unique portfolio of antibody-based solutions for academic and commercial research laboratories. These innovative products will be based on 121 Bio’s core technology platform comprising a proprietary approaches to enzymatic conjugation and single-domain antibody (sdAb) development. 121 Bio’s methodology can produce products that provide powerful new capabilities beyond the capabilities of currently available techniques and reagents. The goal is to create a company that markets a broad range of products used by leading academic and industry laboratories worldwide, to push the frontiers of biology research and biopharmaceutical research.
Celdara Medical builds academic and early-stage innovations into high-potential medical companies, identifying discoveries of exceptional value at the earliest stages and moving them toward the market. We partner with inventors and their institutions, providing the developmental, financial, and business acumen required to bridge discovery and profitability. With robust funding options, a diverse and high impact Programmatic pipeline, and partnerships with world-class academic institutions and industry leaders, Celdara Medical navigates all aspects of a complex industry, accelerating science to improve human health. Website
DecImmune Therapeutics is developing a novel monoclonal antibody aimed at preserving cardiac function following a heart attack. The therapy is designed to be administered during stenting procedures that are typically used to restore blood-flow in response to myocardial infarction. This approach is based on the discovery that blood flow restoration to the heart can trigger a cascade of events that lead to scarring and long-term loss of cardiac function. This pathway, called N2, was discovered and elucidated in the laboratories of the company’s founders at Harvard Medical School, Michael Carroll, PhD, and Francis Moore Jr., MD. Website